Istanbul, Turkey – It was announced when the covid-19 vaccine, developed with Pfizer by Turkish scientists Dr Uğur Şahin and Dr Özlem Türeci, developed against the corona virus, which has infected millions of people worldwide and killed more than 1.3 million people, will be ready. Dr Sahin, who spoke to Reuters in person, gave the gospel.

Another heralded news came last night after it was announced last week that the protection and effectiveness of the Covid-19 vaccine developed by BioNTech, a biotech company founded by US-based Pfizer and Dr Uğur Şahin and Dr Özlem Türeci in Germany, exceeded 90 percent.

Dr Uğur Sahin, founder and CEO of BioNTech, said that the corona virus vaccine could be ready next month.

He said they would apply to the US Food and Drug Administration for an “emergency use permit” and that if all goes well, the vaccine would be ready by mid-December.

“If all goes well, we will be able to obtain an emergency use permit from the United States in the first half of December or early in the second half. Sahin said conditional approval by the European Union could be granted in the second half of December. It all depends on us meeting the conditions,” he said.

Last week, Pfizer and BioNTech announced that the impact rate of the corona virus vaccine had reached 90 percent, while yesterday they shared all the details of the test results with the public. In a statement, it was announced that the success rate of the Covid-19 vaccine developed was 95 percent and no serious side effects were observed.

“If everything goes as we imagined and we get approval, we can start the distribution of vaccines before Christmas (December 25). But as I said, if everything goes completely positive,” he said. Dr Sahin said an application would be made to official authorities in the United States on Friday. An advisory committee at the US National Food and Drug Administration was due to meet on December 8-10 to discuss the vaccine.

The side effects of the Covid-19 vaccine, developed by Pfizer and BioNTech, are very mild and pass immediately.

A statement said that 3.8 percent of volunteers experienced weakness and 2 percent had headaches after receiving the second dose of the vaccine. In older volunteers , the side effect was less.